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Introduction 36 
Despite being a well-established research discipline, pharmacogenomics (PGx) is not yet routinely 37 
applied in patient care. Education is a crucial step for the successful implementation of PGx into the 38 
clinic. We need to offer collaborative, interprofessional approaches that encourage learning about PGx 39 
on an international level. It is especially important that PGx education enables the development of 40 
one’s own thoughts and ideas to be able to understand and implement this rapidly developing field of 41 
science.  42 
  43 
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From science to patient care 44 
PGx is a well-established field of science with more than 20,000 publications listed in the US National 45 
Library of Medicine National Institutes of Health (pubmed.gov) and more than 290,000 findings on 46 
google scholar to date for the terms ‘pharmacogenetics’ OR ‘pharmacogenomics’. But implementing 47 
that knowledge into clinical practice and patient care seems highly heterogeneous and sporadic, 48 
except for a few large scientific efforts. Many barriers to implementing PGx in the clinic have been 49 
identified and are currently challenged (1), such as a lack of insurance coverage, harmonization of lab 50 
structures, procedures, data and interpretation of results. Regulatory authorities such as the Food and 51 
Drug Administration and the European Medicines Agency incorporate PGx information relating to drug 52 
efficacy and safety into product labels. International evidence based guidelines for treatment 53 
adjustments based on PGx results have been produced by CPIC and others and are available through 54 
the Pharmacogenomics Knowledge Base PharmGKB® and the CPIC website. Although PGx guidelines 55 
are published, in many countries medical specialty societies are not involved, recommend their use, or 56 
comment on their content. Increased knowledge about PGx is recognized as crucial for the 57 
implementation of PGx into clinical practice, and importantly the knowledge base within each country 58 
needs to be supported and built up to facilitate clinical implementation across multiple countries. A 59 
new generation of researchers and health-care professionals recognize the potential value that PGx 60 
offers to patient care. Despite PGx being a prominent field of research, its implementation into clinical 61 
practice remains hampered and haphazard. Because education in PGx is crucial for successful 62 
implementation, we need to offer collaborative approaches to disseminate PGx knowledge to the 63 
future generation of healthcare professionals and to develop the knowledge and skill sets to embrace 64 
PGx implementation.  65 
A series of PGx educational programs and concepts for use in pharmacy and medical schools have been 66 
already proposed and undertaken (2). Unfortunately, education is often not providing definitive 67 
answers regarding how PGx testing can be obtained and applied to drug therapy.  68 
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Within the European Ubiquitous Pharmacogenomics (U-PGx) project, we performed a survey asking 69 
about general PGx knowledge in clinical practice (3). This survey was filled out by healthcare 70 
professionals and aimed to assess knowledge gaps and training needs that could be addressed by an 71 
educational program (4). The survey revealed that there is a general interest in PGx application. 72 
However, the interpretation of test results causes uncertainty, the medical knowledge is mainly limited 73 
to university centers, and could be improved especially in postgraduate education. Therefore, 74 
educating and training healthcare professionals of independent academic institutions such as 75 
universities seems to be one of the most important steps to close the gap between the research base 76 
and patient care. 77 
 78 
The European perspective – Ubiquitous Pharmacogenomics (U-PGx) education program 79 
Within the U-PGx implementation project, an educational program is offered that includes web-based 80 
seminars, e-learning opportunities, and real life courses (http://upgx.eu/). 81 
We conducted a survey within the participants of a summer school that was part of the educational 82 
program of U-PGx. The group consisted of 49 participants from eight different countries (UK, 83 
Netherlands, Germany, Slovenia, Greece, Italy, Portugal, and Canada) and worked in hospitals (35%), 84 
ambulatories (7.5%), and academia (57.5%). Whilst researchers and students were commonly 85 
attending the course (51.2%), just 16.3% were physicians working in patient care, and 27.9% were 86 
pharmacists. Figure 1a) provides an overview of the availability of PGx tests in hospital settings, 87 
indications for ordering a PGx test, and locations of PGx data storage as reported by participants of the 88 
U-PGx course.  89 
 90 
Figure 1 91 
 92 
Survey responses of this sample indicated that, within Europe, the utility of PGx is mainly limited to 93 
the research domain, with the local laboratory that generated the PGx data responsible for storage of 94 
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the PGx results; these characteristics are consistent with commonly described barriers to PGx 95 
implementation to patient care (1). Despite the interest in PGx in young health care professionals that 96 
participated in the U-PGx course, there is still a lack of translation of PGx knowledge from the 97 
laboratory and research structures into the clinic. 98 
We also investigated the perceived importance, attributed by the course participants, for several 99 
established drug-gene pairs that have CPIC guidelines available. Figure 1b) shows how the drug-gene 100 
pairs were rated by the participants according to their perceived importance. 101 
When considering drug classes, antithrombotic, and antineoplastic and immunomodulating agents 102 
were ranked the most, presumably because these drugs are associated with severe adverse drug 103 
reactions such as bleeding or leucopenia. The large number of drug-gene pairs concerning drugs acting 104 
on the central nervous system can also be appreciated from figure 1b), as numerous drugs that act on 105 
the central nervous system are metabolized by highly polymorphic cytochrome P450 enzymes 106 
(especially CYP2D6 and CYP2C19). 107 
Although revealed by a small sample, these findings are in line with the perceived meaning of drug-108 
gene pairs as rated by members of the American Society for Clinical Pharmacology and Therapeutics 109 
in 2010 (5). However, a survey addressing a larger and broader population including also more 110 
physicians would be desirable. 111 
For the U-PGx summer school, a comprehensive curriculum was developed that focuses on PGx 112 
knowledge, skills and attitude towards PGx. Table 1 provides the curriculum and didactic goals of the 113 
course illustrating that health professionals need to acquire knowledge and skills to empower them to 114 
practice evidence-based precision medicine.   115 
 116 
Table 1  117 
 118 
What education should address 119 
Education of healthcare professionals: knowledge, skills, attitudes 120 
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Education in PGx should focus on knowledge and skills development, such as how to interpret test 121 
results and how to put the results into context when making treatment decisions. In addition, health 122 
care professionals’ attitudes which mean thoughts and views that may change the use of PGx in patient 123 
care need to be addressed. In a globalized world, we need to foster attitudes towards implementing 124 
PGx, such as considerations when a PGx test is reasonable or should be done independent of ethnic 125 
background or reimbursement features of single countries, and even if it is not covered by available 126 
treatment guidelines. These skills and attitudes might be the crucial step for implementation as most 127 
clinics do not offer a pre-emptive approach. Therefore, implementation also means anticipation of 128 
clinical situations when testing might be required. Furthermore, education needs to help bridge the 129 
gap between PGx treatment guidelines and clinical reality, for instance by training healthcare 130 
practitioners how to interpret and use a genotype-predicted phenotype in the context of interacting 131 
drugs and comorbidities that also affect drug disposition (e.g. hepatic disease, chronic kidney disease). 132 
The available PGx guidelines provide already excellent and reliable information on drug-gene 133 
interactions and the need for treatment modification. However, those guidelines are tools and, even 134 
though easily available, we need to offer education on how to use those tools. 135 
 136 
…and beyond: Education of patients in health competence 137 
It should not be neglected that the general population’s awareness about PGx is increasing, which is 138 
expected to push conservative healthcare professions towards greater use of PGx. Therefore, 139 
information initiatives that target both patients and the wider public should be considered to stimulate 140 
healthcare professionals’ interest in PGx as a beneficial byproduct. To that end, the U-PGx project 141 
provides valuable educational materials which are freely available (http://upgx.eu/). 142 
An interdisciplinary approach between physicians and pharmacists on the one side and research 143 
personal and allied health care professionals on the other side is essential for tackling the most difficult 144 
questions regarding the application of PGx and to offer opportunities to learn from each other. 145 
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Interdisciplinary education has been shown to enhance learning in the health care setting and PGx 146 
should not be an exception. 147 
 148 
Interdisciplinary work 149 
In our own experience, it is highly beneficial, appreciated, and indeed encouraged to work through 150 
interdisciplinary collaborations that foster our own thinking, recognize the multiple aspects involved 151 
in making a treatment decision and thus do not always simply offer a single concrete answer. It is 152 
preferable in PGx education that lecturers engage and encourage team work among and between 153 
specialties. As pointed out technical and conceptual developments in PGx are ongoing. Therefore, 154 
besides imparting knowledge to empower the understanding of PGx testing and treatment concepts, 155 
we need education that equips individuals with the skills to develop their own thoughts and ideas. 156 
Thereby, health care professionals might be enabled to understand and apply this rapidly developing 157 
field of science in a safe and informed manner. Thus, interdisciplinary collaboration and personal 158 
contact with the patient remain central tenets of any comprehensive PGx implementation program. 159 
Science needs to connect closely to clinic and the healthcare setting should not be afraid of science to 160 
overcome the gap between the two of them. The specialty of clinical pharmacology might be 161 
particularly well suited to linking these fields to accelerate the successful translation of PGx from the 162 
bench to the bed. 163 
 164 
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Table 1: Educational needs identified and addressed in a four day U-PGx course 197 
Learning Goal Learning Objective Educational 
Strategy 
Learning 
Domain 
Drug distribution and  
tolerance affected by 
PGx 
Participant learns about the potential 
influence of PGx on phase I and II enzymes 
Teacher-based 
instruction 
Knowledge 
 Participant learns about the potential 
influence of PGx on HLA genes and 
transporters 
Teacher-based 
instruction 
Knowledge 
Concepts of PGx 
guided therapy 
Participant understands ways of how PGx 
knowledge can guide treatment decisions 
Teacher-based 
instruction 
Knowledge 
Selection of patients 
to genotype 
Participant can identify cases where a PGx 
test should be done 
Case-based 
learning 
Skills 
 Participant can appraise critical benefits of 
PGx tests and risks of treating without a 
PGx test 
Case-based 
learning 
Attitudes 
 Participant can identify cases when it is 
reasonable to request a PGx test 
Case-based 
learning 
Skills 
Interdisciplinary 
collaboration 
Participant can discuss PGx topics within 
an interdisciplinary team  
Case-based 
learning 
Skills 
 Participant can appraise different levels of 
knowledge about PGx and develop 
strategies within a team 
Case-based 
learning 
Attitudes 
Methods of 
genotyping 
Participants learns about different 
genotyping techniques and their influence 
on test results 
Teacher-based 
instruction 
Knowledge 
PGx databases and 
resources 
Participant learns about available 
databases and other clinical relevant 
resources such as PharmGKB or PharmVar 
to inform himself on clinical relevant PGx 
knowledge 
Teacher-based 
instruction 
with online 
presentation 
Knowledge 
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Interpretation of test 
results 
Participant learns to translate common 
genotypes into phenotypes 
Case-based 
learning 
Skills 
 Participant considers the integration of 
genotype results with co-medications, and 
comorbidities 
Case-based 
learning 
Skills 
Ethical and legal 
aspects of PGx 
Participant understands ethical and legal 
aspects pertaining to PGx 
Teacher-based 
instruction 
Knowledge/ 
Attitudes 
Ethical considerations Participant learns strategies on how to 
inform patients about genotyping in 
different situations such as direct to 
consumer genotyping or genome project 
genotyping 
Case-based 
learning 
Attitudes 
 Participant learns how to obtain informed 
consent for genotyping in different 
situations such as direct to consumer 
genotyping or genome project genotyping 
Case-based 
learning 
Attitudes 
Clinical impact of 
structures affected by 
polymorphisms on 
drug treatment 
Participant learns about and understands 
important and common sequence 
variations that impact drug therapy 
Teacher-based 
instruction 
Knowledge 
PGx based treatment 
modifications 
Participant can appraise dose 
modifications and contra-indications 
Case-based 
learning 
Skills/ 
Attitudes 
 Participant learns to use PGx test results 
within patients' contexts when making 
treatment decisions 
Case-based 
learning 
Skills 
History of PGx Participant can integrate his PGx 
knowledge in scientific developments of 
the last years 
Teacher-based 
instruction 
Skills/ 
Knowledge 
Implementation of 
PGx 
Participant learns about examples and 
structures from clinical reality for 
Teacher-based 
instruction 
Knowledge 
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successful implementation of PGx into 
patient care 
  198 
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Figure Legends 199 
 200 
Figure: 201 
a) Answers to a survey concerning availability of PGx test (red), reason for ordering a PGx test (blue), 202 
and PGx test data storage (turquoise). 203 
Participants were able to choose more than one answer. Public: health insurances, public health 204 
system; private: companies; In-house: hospital, laboratory; DTC: direct-to-consumer;  205 
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b) Importance of drug-gene pairs as rated by participants. Percentages of participants ranking the ten 206 
most important drug-gene pairs from a list of 56 pairs of drug-gene pairs available CPIC guidelines are 207 
shown. 208 
The color of each bar indicates the class of the drug in the drug-gene pairs: red: antithrombotics; 209 
orange: anti-infectives; brown: antineoplastic and immunomodulating agents; turquoise: drugs acting 210 
on the central nervous system; green: drugs acting on the cardiovascular system; purple: drugs acting 211 
on the musculo-skeletal system; yellow: drugs acting on the alimentary tract and metabolism; grey: 212 
others: antiparasitic products and drugs acting on the respiratory system 213 
CYP: cytochrome P450, VKORC1: vitamin K epoxide reductase complex subunit 1, HLA: human 214 
leukocyte antigen, SLCO1B1: solute carrier organic anion transporter family member 1B1, TPMT: 215 
Thiopurine methyltransferase, UGT1A1: uridine diphosphate glucuronosyltransferase, DPYD: 216 
dihydropyrimidine dehydrogenase, OCT: organic cation transporter, CFTR: cystic fibrosis 217 
transmembrane conductance regulator, IFNL3: interleukin 28B, NAT2: N-acetyltransferase 2. 218 
 219 
Responder rate: n=40 (82%, total: 49 participants from 8 different countries (UK, Netherlands, 220 
Germany, Slovenia, Greece, Italy, Portugal, and Canada) 221 
  222 
